RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
InnoCare Pharma Stock

InnoCare Pharma P/E 2024

InnoCare Pharma P/E

-9.31

Ticker

9969.HK

ISIN

KYG4783B1032

WKN

A2PVC2

As of Oct 25, 2024, InnoCare Pharma's P/E ratio was -9.31, a -27.15% change from the -12.78 P/E ratio recorded in the previous year.

The InnoCare Pharma P/E history

InnoCare Pharma Aktienanalyse

What does InnoCare Pharma do?

InnoCare Pharma Ltd is a biopharmaceutical company based in China, focused on researching, developing, and marketing novel therapies for the treatment of severe diseases. The company was founded in 2015 by Dr. Jasmine Cui with the goal of developing innovative therapies that improve patients' lives and advance medical progress. InnoCare has become a key player in the biopharmaceutical industry in China since its establishment and has been listed on the Hong Kong Stock Exchange since 2019. The company has a diversified business model, with a focus on research and development, product marketing and licensing, and collaboration with other companies to develop new therapies. InnoCare specializes in various therapeutic areas, including oncology, immunology, neurology, and dermatology. The company has a wide portfolio of products in clinical development, including small molecules and antibodies that aim to meet unmet medical needs of patients. One of InnoCare's most promising products is ICP-192, a small molecule that can be used to treat various types of cancer. ICP-192, developed by InnoCare itself, is currently in phase III clinical trials. Other important products of InnoCare include ICP-151, a small molecule for treating chronic respiratory diseases, ICP-105, an antibody for treating severe autoimmune diseases, and ICP-601, a small molecule for treating skin inflammation and psoriasis. InnoCare has also entered into several strategic partnerships to expand its growth opportunities and product portfolio. One of these partnerships is collaboration with Roche for the development of ICP-192. InnoCare has also entered into a cooperation agreement with Sanofi for the development of ICP-105 and a licensing agreement with Novartis for the marketing of ICP-151 in China. InnoCare Pharma Ltd is an emerging company in the biopharmaceutical industry, focusing on the development and marketing of innovative therapies for the treatment of severe diseases. The company has a diversified business model based on research and development, product marketing and licensing, and collaboration with other companies for the development of new therapies. With a wide portfolio of products in clinical development and strategic partnerships with renowned companies, InnoCare has great potential for further growth and success in the future. InnoCare Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering InnoCare Pharma's P/E Ratio

The Price to Earnings (P/E) Ratio of InnoCare Pharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing InnoCare Pharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of InnoCare Pharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in InnoCare Pharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about InnoCare Pharma stock

What is the price-to-earnings ratio of InnoCare Pharma?

The price-earnings ratio of InnoCare Pharma is currently -9.31.

How has the price-earnings ratio of InnoCare Pharma changed compared to last year?

The price-to-earnings ratio of InnoCare Pharma has increased by -27.15% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of InnoCare Pharma high compared to other companies?

Yes, the price-to-earnings ratio of InnoCare Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of InnoCare Pharma affect the company?

An increase in the price-earnings ratio of InnoCare Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of InnoCare Pharma affect the company?

A decrease in the price-earnings ratio of InnoCare Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of InnoCare Pharma?

Some factors that influence the price-earnings ratio of InnoCare Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does InnoCare Pharma pay?

Over the past 12 months, InnoCare Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, InnoCare Pharma is expected to pay a dividend of 0 CNY.

What is the dividend yield of InnoCare Pharma?

The current dividend yield of InnoCare Pharma is .

When does InnoCare Pharma pay dividends?

InnoCare Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of InnoCare Pharma?

InnoCare Pharma paid dividends every year for the past 0 years.

What is the dividend of InnoCare Pharma?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is InnoCare Pharma located?

InnoCare Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von InnoCare Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of InnoCare Pharma from 10/25/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.

When did InnoCare Pharma pay the last dividend?

The last dividend was paid out on 10/25/2024.

What was the dividend of InnoCare Pharma in the year 2023?

In the year 2023, InnoCare Pharma distributed 0 CNY as dividends.

In which currency does InnoCare Pharma pay out the dividend?

The dividends of InnoCare Pharma are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von InnoCare Pharma

Our stock analysis for InnoCare Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InnoCare Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.